Alpha-lipoic acid (ALA, also called thioctic acid) is a dithiol compound that is unique in the antioxidant network because it functions both as a direct antioxidant in its reduced form (dihydrolipoic acid, DHLA) and as a metabolic cofactor in its oxidised form (ALA itself) in the pyruvate dehydrogenase complex and in the alpha-ketoglutarate dehydrogenase complex of the TCA cycle. ALA is synthesised endogenously from cysteine and from octanoic acid in the mitochondria, and it is also obtained from the diet (particularly from organ meats, spinach, broccoli, and tomatoes) and from supplements. The unique dual function of ALA — as both a metabolic cofactor and an antioxidant — makes it one of the most versatile and therapeutically useful compounds in nutritional medicine, and it explains why ALA has been extensively studied for its effects on diabetic neuropathy, insulin sensitivity, cardiovascular health, and cognitive function.
ALA as a Metabolic Cofactor
Alpha-lipoic acid is an essential cofactor for two enzyme complexes in the TCA cycle — the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (alpha-KGDH). Both of these enzyme complexes require multiple cofactors — PDC requires thiamine pyrophosphate (TPP, the active form of vitamin B1), lipoic acid, CoA, FAD (from riboflavin), and NAD (from niacin); alpha-KGDH requires TPP, lipoic acid, CoA, FAD, and NAD in addition to calcium. Lipoic acid is covalently attached to the lysine residue of the E2 subunit of these enzyme complexes (forming the lipoyl domain), and it functions as a swinging arm that transfers the acyl group between the active sites of the different subunits of the complex. Without adequate lipoic acid, the PDC and alpha-KGDH complexes cannot function, pyruvate cannot be converted to acetyl-CoA, alpha-ketoglutarate cannot be converted to succinyl-CoA, and the TCA cycle cannot proceed. This metabolic cofactor function of ALA is the foundation of its therapeutic effects in diabetes and in the metabolic syndrome.
The clinical importance of ALA for metabolic health is underscored by the observation that ALA supplementation improves insulin sensitivity and reduces blood glucose levels in people with type 2 diabetes and with insulin resistance. The mechanism involves the activation of the AMP-activated protein kinase (AMPK) enzyme (which is the master regulator of cellular energy metabolism), the enhancement of the translocation of GLUT4 glucose transporters to the cell membrane (which increases glucose uptake by muscle and fat cells), and the reduction of the oxidative stress and the inflammation that are the primary drivers of insulin resistance. Multiple RCTs have demonstrated that ALA supplementation at 600-1,800mg daily reduces fasting blood glucose, reduces HbA1c, and improves insulin sensitivity in people with type 2 diabetes.
ALA as an Antioxidant
In its reduced form (dihydrolipoic acid, DHLA), ALA is one of the most potent antioxidants in the aqueous phase of the cell — it directly neutralises the reactive oxygen species (ROS) and the reactive nitrogen species (RNS) that are generated as byproducts of normal cellular metabolism and as products of the inflammatory response. ALA is unique among antioxidants in that it is both water-soluble and fat-soluble (it dissolves in both the aqueous and the lipid phases of the cell), which allows it to protect both the aqueous compartments (cytoplasm, mitochondrial matrix) and the lipid compartments (cell membranes, mitochondrial membranes) from oxidative damage. ALA also regenerates other antioxidants — it reduces the vitamin C radical back to active vitamin C, it reduces the vitamin E radical back to active vitamin E at the lipid-water interface, and it helps to maintain glutathione in its reduced (active) form. This regenerative capacity of ALA in the antioxidant network is one of the most important features of its antioxidant activity.
The clinical importance of ALA as an antioxidant is most clearly demonstrated in diabetic neuropathy — the peripheral nerve damage that is one of the most common and most debilitating complications of type 1 and type 2 diabetes. The mechanism of diabetic neuropathy involves the oxidative damage to the peripheral nerves that results from the combination of elevated blood glucose (which generates ROS through the polyol pathway), the advanced glycation end-products (AGEs) that form when glucose reacts with proteins and lipids, and the impaired antioxidant defence that is characteristic of diabetes. ALA has been shown to improve the symptoms of diabetic neuropathy (including pain, burning, numbness, and paraesthesias) in multiple RCTs, and it is approved for the treatment of diabetic neuropathy in Germany (as a prescription medication) and is widely used as an off-label treatment for diabetic neuropathy worldwide.
Practical Application
For general ALA supplementation, the evidence-based dose is 300-600mg of alpha-lipoic acid daily (as the free acid form, which is better absorbed than the sodium salt form). For the treatment of diabetic neuropathy, the dose is 600-1,800mg daily, divided into two or three doses to maintain stable blood levels throughout the day. ALA is generally well-tolerated with no significant adverse effects at doses up to 1,800mg daily, though very high doses may produce gastrointestinal symptoms (nausea, abdominal pain) or may cause a transient rise in blood glucose. For comprehensive antioxidant support, ALA pairs well with acetyl-L-carnitine (which has complementary effects on mitochondrial function and which is also used for the treatment of diabetic neuropathy), with CoQ10 (which is required for the function of the electron transport chain and which is regenerating vitamin E), with vitamin C (which is regenerated by ALA in the aqueous phase), and with vitamin E (which is regenerated by ALA at the lipid-water interface).
A quality supplement routine can make a real difference to your results.
Leave a Reply